PennyStocksUpdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 03/11/2013 -- Pandora rocks for a change Shares of Pandora Media Inc (NYSE:P) soared 18% on Friday after posting strong quarterly results. The music-discovery pioneer posted a narrower-than-expected loss of $0.04 a share, with revenue soaring 54% to $125.1 million.
The news gets better. After watching it monthly listeners fall from 67.1 million in December to 65.6 million in January, February's tally clocked in at 67.1 million unique listeners. That's not too shabby of a turnaround for the shortest month of the year. Pandora Media Inc (NYSE:P)'s revenue guidance -- calling for $120 million to $125 million for the current quarter and $600 million to $620 million for the year -- also came in ahead of Wall Street targets.
For a FREE INSTANT ANALYSIS of P, please visit here
Needham biotech Celldex Therapeutics Inc. (NASDAQ:CLDX) rebounded a day after it reported a loss for 2012 and for the fourth quarter. Celldex reported a net loss of $16.8 million, or 27 cents per share, for the quarter, compared to a loss of $12.7 million, or 29 cents, in 2011. For the twelve months, Celldex reported a net loss of $59.1 million, or $1.02 per share, compared to a loss of $44.8 million, or $1.13, last year. Friday’s jump came after analysts at Leerink Swann initiated coverage for Celldex with a rating of outperform, setting a price of $18.
Should A Trader Buy Or Sell CLDX Now: CHECK HERE
Quicksilver Resources Inc (NYSE:KWK) shares jumped 14.59% to $2.12 in the last trading session. The KWK‘s stock had its “neutral” rating reaffirmed by Zacks in a report released on Feb. 27. They currently have a $1.75 target price on the stock.
Additionally, the company, on Feb. 25, reported a fourth quarter loss of $1.10 billion or $6.47 per share, versus net income of $23.53 million or $0.14 per share in the same period last year. Adjusted net loss for the quarter was $2.39 million or $0.01 per share. Meanwhile, revenues for the three-month period dipped to $179.07 million from $223.09 million in the same quarter a year earlier. Analysts expected the company to report earnings of $0.01 per share on revenues of $168.69 million for the quarter.
How To Trade KWK After The Recent Momentum? Find Out Here
Astex Pharmaceuti (NASDAQ:ASTX) is very active today and traded between $4.12 - 4.58 with total traded volume of 2838357 shares. At a current price of 4.52, ASTX is +0.40 - +9.71% from the previous close of $4.12. Moreover, At Current Market Price, ASTX is in the distance of +34.38% from its 50-day Moving Average price of $3.3635 and +52.61% from its 200-day Moving Average price of $2.9618.
Should Investors Buy ASTX Now? Free Sign Up Here For ASTX Analyst Report
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)